Kukje Pharm said Monday that it has signed an agreement with Eyegene to co-develop EG-Mirotin, the world's first treatment for non-proliferative diabetic retinopathy.According to Kukje, EG-Mirotin is a new-concept biological drug that treats diabetic retinopathy by relieving symptoms of recurrent sw
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) has welcomed the government’s additional designation of the industry to national high-technology strategic industries.“We sincerely welcome the government's designation of the biopharma industry as an additional national high-
Merz Aesthetics is a global leader in aesthetics, a field known as "a beauty expert" to healthcare professionals and consumers alike. However, what is less well known is that Merz's leadership in aesthetics has been accompanied by a great deal of research and development (R&D) and scientific endeavo
AriBio said on Tuesday it has signed an agreement to take over the management of Solux, a Kosdaq-listed company. AriBio said in a public filing that its CEO Jung Jae-joon will secure management control of Solux's largest shareholder, CEO Kim Bok-deok, and that Solux will raise 50 billion won ($37.3
Calls are mounting for Korea to reduce foreign dependency and increase the self-supply ratio of active pharmaceutical ingredients (APIs) to prepare for the escalating hegemonic rivalry between the U.S. and Korea.On March 31, the U.S. Treasury Department announced a detailed guideline on exempting ta
Samsung Electronics and Samsung Medison said they would unveil up-to-date medical devices and artificial intelligence-based diagnostic aid functions by participating in the 38th Korea International Medical & Hospital Equipment Show (KIMES) at COEX, southern Seoul, from Thursday to Sunday.Samsung Med
The Korea Disease Control and Prevention Agency (KDCA) will establish the “National Standard Implementation Plan for Medical Devices in 2023” to lead international standards and help domestic medical equipment makers advance overseas.The main content of the implementation plan includes a push to win
The Korea Innovative Medicines Consortium (KIMCo) said Monday that it would conduct a joint investment project to help strengthen the Korean biopharmaceutical industry’s global competitiveness.The consortium said that the joint investment project aims to create synergy in researching, developing, an
Hypoesthesia, one of the aftereffects of Covid-19, also causes neurological aftereffects, such as brain fog (vacancy) and memory loss, a study showed.Professor Jeong Young-hee of the Neurology Department at Myongji Hospital said so while releasing her analysis of 440 patients who visited the hospita
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) has vowed to focus on building an ecosystem to create new blockbuster drugs and enhance industrial competitiveness this year.At its general meeting on Tuesday, the association finalized its business plan, composed of 16 core t
Handok, which reaffirmed its strong position in the diabetes area with sales of 100 billion won ($80 million) in this sector last year, has thrown a gauntlet to the anticancer treatment market.The company will also continue to secure competitive products to continue its growth pace, according to its
Parkinson’s disease inevitably accompanies long-term fights on the part of patients. Therefore, efforts are being made in and out of the medical community to raise patients’ survival rates and improve their quality of life.“Percept PC,” developed by Medtronic using deep brain stimulation (DBS), is a
Cancer has taken off its label of “incurable” thanks to technological development but remains a serious disease that is hard to treat. As a result, patients and their families are particularly thirsty for information about whether they get the treatment they need on time and what kind of care they s
Yuhan Corp. is hastening its steps to develop new drugs that can succeed Leclaza (lazertinib), which is cruising as a homegrown blockbuster for cancer treatment.In a recent interview with reporters covering the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, Yonhan Corp. CEO Cho Wook-
Next&Bio, a precision medicine platform based on organoids, will make a poster presentation of a study confirming the possibility of establishing a patient sample-based pancreatic and biliary tract cancer organoid model.The presentation will be made at the American Society of Clinical Oncology's Dig
Myongji Hospital said it has received the highest grade of Grade 1 in the first adequacy evaluation of dementia treatment.The Health Insurance Review and Assessment Service (HIRA) conducted its first dementia adequacy assessment on 889 medical institutions that treated new dementia patients from Oct
Korean College of Rheumatology (KCR) said Tuesday that it has successfully attracted the Asia Pacific League of Associations for Rheumatology conference in 2026 (APLAR 2026).Four countries competed to lure the event, including India, Malaysia, and Taiwan. In the general assembly from Dec. 6-9, APLAR
Lunsumio, Roche Korea’s lymphoma treatment, has become the first drug designated as the subject of the government’s Global Innovative products on Fast Track (GIFT).The Ministry of Food and Drug Safety said Tuesday that it had picked Lunsumio Inj. as the first product of the government’s GIGT system
Daewoong Pharmaceutical held a symposium on Fexuclue, titled “The new wave of GERD (gastroesophageal reflux disease) Treatment,” on Thursday at its headquarters in Samseong-dong, southern Seoul.Thirty-eight “key opinion leaders” from overseas, including the leadership of the Philippine gastrointesti
Is it necessary for biopharmaceutical companies to introduce the “ESG (environment, society, and governance) management,” which has emerged as a new corporate keyword for businesses worldwide?If so, how should biopharma firms prepare for “ESG management?”What “ESG management” strategies are global b